Professional experience

Following the acquisition of Couloir Bio, I transitioned to Intercellular to lead the company's scientific vision and R&D efforts.

I guided Couloir Bio’s scientific direction and R&D priorities, applying pathway-centric analysis of multimodal datasets to reveal new biological mechanisms and enable more individualized treatment approaches in oncology. In June 2026, Couloir Bio was acquired by Intercellular, and I joined the company as Chief Scientific Officer.

I defined and led Cellazon’s scientific mission and long-term R&D strategy, focusing on leveraging multimodal data in a mechanistically interpretable way to identify novel therapeutic targets and biomarkers.

I lead a team of exceptionally talented scientists dedicated to understanding and modeling cell signaling pathways, with the goal of translating this knowledge into efficient target discovery. In parallel, we develop novel methods for discovering antibodies against these targets, both through empirical approaches and in silico techniques.

As part of Genentech’s vibrant scientific community, I led a research group of interdisciplinary scientists focused on integrating concepts from physics and mathematics with cell biology and immunology to advance in silico discovery of drug targets and biomarkers in cancer immunology.

My team was a part of a larger group headed by Dr. Leonore Herzenberg. I provided technical leadership to a small team of extremely capable software engineers and researchers in projects of computational immunology and statistics.